Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 18

Submit an article Journal homepage

354

Views

CrossRef citations to date

Altmetric

Review

Treatment strategies for Behçet's disease

Izzet Fresko Department of Rheumatology, Cerrahpasa Medical Faculty, Cerrahpasa Tip Fakultesi, Ic Hastaliklari ABD, 34300 Aksaray, Istanbul, Turkey +90 532 3251491; +90 212 5890808; [email protected]

Hasan Yazici Department of Rheumatology, Cerrahpasa Medical Faculty, Cerrahpasa Tip Fakultesi, Ic Hastaliklari ABD, 34300 Aksaray, Istanbul, Turkey +90 532 3251491; +90 212 5890808; [email protected]

Pages 3211-3219 | Published online: 28 Nov 2008

Cite this article
https://doi.org/10.1517/14656560802457749

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999;341:1284-91
PubMed Web of Science ®Google Scholar
International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80
PubMed Web of Science ®Google Scholar
González-Gay MA, García-Porrúa C, Brañas F, et al. Epidemiologic and clinical aspects of Behçet's disease in a defined area of Northwestern Spain, 1988-1997. J Rheumatol 2000;27:703-7
PubMed Web of Science ®Google Scholar
Yurdakul S, Günaydin I, Tüzün Y, et al. The prevalence of Behçet's syndrome in a rural area in northern Turkey. J Rheumatol 1988;15:820-2
PubMed Web of Science ®Google Scholar
Azizlerli G, Köse AA, Sarica R, et al. Prevalence of Behçet's disease in Istanbul, Turkey. Int J Dermatol 2003;42:803-6
PubMed Web of Science ®Google Scholar
Yazici H, Tüzün Y, Pazarli H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984;43:783-9
PubMed Web of Science ®Google Scholar
KarIncaoglu Y, Borlu M, Toker SC, et al. Demographic and clinical properties of juvenile onset Behçet's disease: a controlled multicenter study. J Am Acad Dermatol 2008;58:579-84
PubMed Web of Science ®Google Scholar
Tunc R, Keyman E, Melikoglu M, et al. Target organ associations in Turkish patients with Behçet's disease: a cross sectional study by exploratory factor analysis. J Rheumatol 2002;29:2393-6
PubMed Web of Science ®Google Scholar
Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60-76
PubMed Web of Science ®Google Scholar
Yurdakul S. Evidence-based treatment of Behçet's syndrome. Clin Exp Rheumatol 2006;24(5 Suppl 42):S53-5
Google Scholar
Alpsoy EH Er, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999;135:529-3
PubMed Web of Science ®Google Scholar
Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001;44:2686-92
PubMed Web of Science ®Google Scholar
Calgüneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology 1996;192:125-8
PubMed Web of Science ®Google Scholar
Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997;38:444-54
PubMedGoogle Scholar
Mumcu G, Ergun T, Elbir Y, et al. Clinical and immunological effects of azithromycin in Behçet's disease. J Oral Pathol Med 2005;34:13-6
PubMedGoogle Scholar
Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322:281-5
PubMed Web of Science ®Google Scholar
Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behçet's disease. J Am Acad Dermatol 1994;31:617-9
PubMed Web of Science ®Google Scholar
Azizlerli G, Sarica R, Köse A, et al. Interferon alfa-2a in the treatment of Behçet's disease. Dermatology 1996;192:239-41
PubMedGoogle Scholar
Boyvat A, Sişman-Solak C, Gürler A. Long-term effects of interferon alpha 2A treatment in Behçet's disease. Dermatology 2000;201:40-3
PubMed Web of Science ®Google Scholar
Georgiou S, Monastirli A, Pasmatzi E, et al. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease. J Intern Med 1998;243:367-72
PubMed Web of Science ®Google Scholar
O'Duffy JD, Calamia K, Cohen S, et al. Interferon-alpha treatment of Behçet's disease. J Rheumatol 1998;25:1938-44
PubMed Web of Science ®Google Scholar
Zouboulis CC, Treudler R, Orfanos CE. Adamantiades-Behçet disease. Therapeutic administration of systemic recombinant interferon-alpha-2a. Hautarzt 1993;44:440-5
PubMedGoogle Scholar
Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105
PubMed Web of Science ®Google Scholar
Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50
PubMed Web of Science ®Google Scholar
Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 2006;45:348-52
PubMed Web of Science ®Google Scholar
Yurdakul S, Yazici H, Tüzün Y, et al. The arthritis of Behçet's disease: a prospective study. Ann Rheum Dis 1983;42:505-15
PubMed Web of Science ®Google Scholar
Moral F, Hamuryudan V, Yurdakul S, Yazici H. Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 1995;13:493-5
PubMed Web of Science ®Google Scholar
Calgüneri M, Kiraz S, Ertenli I, et al. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease. A randomized clinical trial. Arthritis Rheum 1996;39:2062-5
PubMed Web of Science ®Google Scholar
Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40:769-74
PubMed Web of Science ®Google Scholar
Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 1992;76:241-3
PubMed Web of Science ®Google Scholar
BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 1988;20:136-43
PubMed Web of Science ®Google Scholar
Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989;1:1093-6
PubMed Web of Science ®Google Scholar
Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behçet's disease–review and basis for recommendations. Rheumatology (Oxford) 2007;46:736-41
PubMed Web of Science ®Google Scholar
Theodossiadis PG, Markomichelakis N, Sfikakis PP. Tumour necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retinal 2007;27:399-413
PubMed Web of Science ®Google Scholar
Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005;52:2478-84
PubMed Web of Science ®Google Scholar
Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004;140:404-6
PubMed Web of Science ®Google Scholar
Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8
PubMed Web of Science ®Google Scholar
Wechsler B, Sablé-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 2004;22(4 Suppl 34):S14-6
PubMed Web of Science ®Google Scholar
Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol 2005;26:83-92
PubMedGoogle Scholar
Arayssi T, Hamra R, Homeidan F, et al. The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis. Clin Exp Rheumatol 2005;23:427
PubMed Web of Science ®Google Scholar
Giansanti F, Barbera ML, Virgili G, et al. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease. Eur J Ophthalmol 2004;14:445-8
PubMed Web of Science ®Google Scholar
Lanthier N, Parc C, Scavennec R, et al. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients. Presse Med 2005;34:916-8
PubMed Web of Science ®Google Scholar
Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, et al. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 2001;358:1644
PubMed Web of Science ®Google Scholar
Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-6
PubMed Web of Science ®Google Scholar
Triolo G, Vadalà M, Accardo-Palumbo A, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis 2002;61:560-1
PubMed Web of Science ®Google Scholar
Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71
PubMed Web of Science ®Google Scholar
Kötter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004;33:311-9
PubMed Web of Science ®Google Scholar
Kötter I, Zierhut M, Eckstein A, et al. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis. Adv Exp Med Biol 2003;528:521-3
PubMed Web of Science ®Google Scholar
Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 2000;8:293-301
PubMed Web of Science ®Google Scholar
Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-9
PubMed Web of Science ®Google Scholar
Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006;244:1692-5
PubMed Web of Science ®Google Scholar
Krause L, Turnbull JR, Torun N, et al. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease. Adv Exp Med Biol 2003;528:511-9
PubMed Web of Science ®Google Scholar
Calgüneri M, Oztürk MA, Ertenli I, et al. Effects of interferon alpha treatment on the clinical course of refractory Behçet's disease: an open study. Ann Rheum Dis 2003;62:492-3
PubMed Web of Science ®Google Scholar
Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-35
PubMed Web of Science ®Google Scholar
Krause L, Altenburg A, Pleyer U, et al. Long term visual prognosis of patients with Adamantiades- Behçet's disease treated with interferon-alpha-2a. J Rheumatol 2008;35:896-903
PubMed Web of Science ®Google Scholar
Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr Med Assoc J 2002;4(Suppl 11):928-30
PubMed Web of Science ®Google Scholar
Lashay AR, Rahimi A, Chams H, et al. Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behçet's disease. Eye 2003;17:762-6
PubMedGoogle Scholar
Mochizuki M, Masuda K, Sakane T, et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc 1991;23:3343-6
PubMed Web of Science ®Google Scholar
Tunc R, Saip S, Siva A, Yazici H. Cerebral venous thrombosis is associated with major vessel disease in Behçet's syndrome. Ann Rheum Dis 2004;63:1693-4
PubMedGoogle Scholar
Kahraman O, Celebi-Onder S, Kamali S, et al. Long term course of deep venous thrombosis in patients with Behçet's Disease. American College of rheumatology 67th Annual meeting; Orlando, Wiley, New Jersey. 2003;48:S385
Google Scholar
Ahn JK, Lee YS, Jeon CH, et al. Treatment of venous thrombosis associated with Behçet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008;27:201-5
PubMed Web of Science ®Google Scholar
Tüzün H, Beşirli K, Sayin A, et al. Management of aneurysms in Behçet's Syndrome: an analysis of 24 patients. Surgery 1997;121:150-6
PubMed Web of Science ®Google Scholar
Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behçet's syndrome: a report of 24 cases. Br J Rheumatol 1994;33:48-51
PubMedGoogle Scholar
Tüzün H, Hamuryudan V, Yildirim S, et al. Surgical therapy of pulmonary arterial aneurysms in Behçet's syndrome. Ann Thorac Surg 1996;61:733-5
PubMed Web of Science ®Google Scholar
Cil BE, Geyik S, Akmangit I, et al. Embolization of a giant pulmonary artery aneurysm from Behçet disease with use of cyanoacrylate and the ‘bubble technique’. J Vasc Interv Radiol 2005;16:1545-9
PubMedGoogle Scholar
Hamuryudan VT Er, Seyahi E, Akman C, et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med 2004;117:867-70
PubMed Web of Science ®Google Scholar
O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med 1984;76:75-84
PubMed Web of Science ®Google Scholar
Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci 1998;159:181-5
PubMed Web of Science ®Google Scholar
Fujikawa K, Aratake K, Kawakami A, et al. Successful treatment of refractory neuro-Behçet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 2007;66:136-7
PubMed Web of Science ®Google Scholar
Alty JE, Monaghan TM, Bamford JM. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade. Clin Neurol Neurosurg 2007;109:279-81
PubMed Web of Science ®Google Scholar
Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry 2005;76:1733-5
PubMed Web of Science ®Google Scholar
Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol 2005;32:181-3
PubMed Web of Science ®Google Scholar
Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999;106:586-9
PubMed Web of Science ®Google Scholar
Kötter I, Günaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications–results of a retrospective analysis of 117 cases. Clin Rheumatol 2006;25:482-6
PubMed Web of Science ®Google Scholar
Kato Y, Numaga J, Kato S, et al. Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 2001;29:335-6
PubMed Web of Science ®Google Scholar
Iida M, Kobayashi H, Matsumoto T, et al. Postoperative recurrence in patients with intestinal Behçet's disease. Dis Colon Rectum 1994;37:16-21
PubMed Web of Science ®Google Scholar
Postema PT, Den Haan P, Van Hagen PM, Van Blankenstein M. Treatment of colitis in Behçet's disease with thalidomide. Eur J Gastroenterol Hepatol 1996;8:929-31
PubMedGoogle Scholar
Lee JH, Kim TN, Choi ST, et al. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007;22:24-7
PubMedGoogle Scholar
Kram MT, May LD, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003;46:118-21
PubMedGoogle Scholar
Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001;120:995-9
PubMed Web of Science ®Google Scholar
Travis SP, Czajkowski M, McGovern DP, et al. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001;49:725-8
PubMed Web of Science ®Google Scholar
Kaneko F, Tojo M, Sato M, Isogai E. The role of infectious agents in the pathogenesis of Behçet's disease. Adv Exp Med Biol 2003;528:181-3
PubMedGoogle Scholar
Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behçet's disease. Clin Exp Rheumatol 2003;21(4 Suppl 30):S44-8
PubMed Web of Science ®Google Scholar
Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis 2004;63:1445-9
PubMedGoogle Scholar
Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet's disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2008;Jan 31
Google Scholar
Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet's disease: a double blind, placebo controlled, cross-over study. J Dermatol 2002;29:267-79
PubMed Web of Science ®Google Scholar
Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect oro-genital ulcers in Behçet's syndrome: a randomized double blind trial. Br J Rheumatol 1988;27:300-2
PubMedGoogle Scholar
Denman AM, Hollingworth P, Webster ADB, et al. Failure of transfer factor in the treatment of Behçet's syndrome: a double blind trial. In: T Lehner, CG Barnes, Editors, Behçet's Syndrome. London, Academic Press; 1979. p. 227-89
Google Scholar
Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm 2007;15:63-70
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Treatment strategies for Behçet's disease

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Treatment strategies for Behçet's disease

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date